Cabo funds the next Exelixis bet
- CABOMETYX generates the vast majority of current product revenue for the company.
- The drug is the number one prescribed targeted therapy in renal cell carcinoma, a common form of kidney cancer.
- The neuroendocrine tumor indication has surpassed 50% new patient market share, though revenue growth is gradual.
- Zanzalintinib is under FDA review for colorectal cancer with an updated March 3, 2027 decision date.
- The main risk is concentration because most current revenue depends on cabozantinib.
One big drug, one big follow-up
Exelixis is in a stronger spot than many biotech companies because it already makes real money. CABOMETYX, its brand name for cabozantinib, funds the company while it runs trials and buys back stock. The core business captures more than 50% new patient market share in second-line plus neuroendocrine tumors, known as NET.
The bull case is simple. Cabo is still growing in kidney cancer, expanding 11% year-over-year in the third quarter. The company also has a clear path to a second major franchise if the FDA approves zanzalintinib for colorectal cancer on March 3, 2027.
The bear case centers on the pace of growth and trial delays. The FDA pushed the zanzalintinib colorectal cancer decision from December 2026 to March 2027, and a key kidney cancer data readout slipped into the first quarter of 2027. Also, the NET indication is ramping slower than initially expected. Until zanzalintinib is approved and starts selling, Exelixis remains mostly a one-product story.
Finn considers the setup balanced. Exelixis has strong current performance and financial health, but the stock needs proof that the next drug can become a broad commercial success.
Cabo pays the bills
Exelixis makes most of its money by selling CABOMETYX in the United States. It also receives collaboration revenue, mainly royalties from Ipsen and Takeda, which sell cabozantinib outside the United States.
The business is heavily tied to U.S. cabo demand. In early 2026, net product revenue made up over 90% of total revenue. This means the company still depends heavily on domestic prescriptions.
The company uses this cash to fund cancer trials, especially zanzalintinib, and to support business development. This model works well when cabo keeps growing and trials hit. It breaks if payers cut net prices, doctors switch to rivals, or zanzalintinib fails to win broad approval.
What Exelixis sells and tests
CABOMETYX in renal cell carcinoma
This is the core market for Exelixis. RCC is kidney cancer, and CABOMETYX is the number one prescribed targeted treatment there.
CABOMETYX in neuroendocrine tumors
The FDA approved CABOMETYX for pNET and epNET in 2025. The drug captures high new patient share, though the indolent nature of the disease slows the revenue ramp.
Zanzalintinib in colorectal cancer
This is the key next-drug bet. The FDA accepted the NDA for zanzalintinib plus atezolizumab, with a March 3, 2027 PDUFA decision date.
Zanzalintinib in non-clear cell RCC
STELLAR-304 tests zanzalintinib plus nivolumab against sunitinib in untreated non-clear cell kidney cancer. Top-line results are expected in the first quarter of 2027.
Early oncology pipeline
Exelixis is testing earlier drugs such as XL309, XB010, XB628, XB371, and newly nominated XL558. These could matter later, but they are not the main value driver today.
Partnered legacy products
COTELLIC and MINNEBRO came from Exelixis research and are marketed through partners. They add breadth, but cabo remains the main business.
Revenue is still concentrated
Net product revenue makes up roughly 91% of total revenue, meaning Exelixis depends primarily on U.S. cabozantinib sales.
What could go wrong
Zanzalintinib delay and label risk
High impact · Medium oddsThe FDA delayed the colorectal cancer decision to March 3, 2027. Additionally, the non-liver metastasis subgroup failed to hit statistical significance for overall survival. This introduces the risk of a narrower label than investors hope.
Cabo growth slows
High impact · Medium oddsMost revenue still comes from cabozantinib. The neuroendocrine tumor launch is ramping gradually due to patient kinetics. If kidney cancer share also weakens, growth will stall.
STELLAR-304 data miss
High impact · Medium oddsSTELLAR-304 is the next major zanzalintinib kidney cancer trial. A weak result in early 2027 would hurt the case that zanzalintinib can become a broad franchise.
Payer discounts pressure margins
Medium impact · Medium oddsManagement expects 2026 gross-to-net deductions of approximately 30 percent. Gross-to-net is the gap between list price and what the company keeps after rebates and fees. A higher percentage means Exelixis keeps less of each sale.
Competition changes doctor habits
Medium impact · Medium oddsCABOMETYX competes with other targeted drugs and immune therapy combinations. It leads in renal cell carcinoma today, but doctors can change prescribing if rivals show better data or cleaner safety profiles.
In one breath
How does Exelixis make money?
Exelixis mainly sells CABOMETYX in the United States. It also earns collaboration revenue, including royalties from Ipsen and Takeda for cabozantinib sales outside the United States.
What is the biggest upcoming Exelixis catalyst?
The biggest dated catalyst is the FDA decision for zanzalintinib in colorectal cancer on March 3, 2027. Investors will also watch STELLAR-304 data in non-clear cell kidney cancer in the first quarter of 2027.
Why does concentration risk matter for EXEL?
Most current revenue depends on cabozantinib. If CABOMETYX loses share, faces access pressure, or has a safety issue, Exelixis would feel it quickly because zanzalintinib is not yet a major seller.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Exelixis, Inc. in Finn's Biotechnology industry ranking.

